Title |
The value of core lab stress echocardiography interpretations: observations from the ISCHEMIA Trial
|
---|---|
Published in |
Cardiovascular Ultrasound, December 2015
|
DOI | 10.1186/s12947-015-0043-2 |
Pubmed ID | |
Authors |
Akihisa Kataoka, Marielle Scherrer-Crosbie, Roxy Senior, Gilbert Gosselin, Denis Phaneuf, Gabriela Guzman, Gian Perna, Alfonso Lara, Sasko Kedev, Andrea Mortara, Mohammad El-Hajjar, Leslee J. Shaw, Harmony R. Reynolds, Michael H. Picard |
Abstract |
Stress echocardiography (SE) is dependent on subjective interpretations. As a prelude to the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) Trial, potential sites were required to submit two SE, one with moderate or severe left ventricular (LV) myocardial ischemia and one with mild ischemia. We evaluated the concordance of site and core lab interpretations. Eighty-one SE were submitted from 41 international sites. Ischemia was classified by the number of new or worsening segmental LV wall motion abnormalities (WMA): none, mild (1 or 2) or moderate or severe (3 or more) by the sites and the core lab. Core lab classified 6 SE as no ischemia, 35 mild and 40 moderate or greater. There was agreement between the site and core in 66 of 81 total cases (81 %, weighted kappa coefficient [K] =0.635). Agreement was similar for SE type - 24 of 30 exercise (80 %, K = 0.571) vs. 41 of 49 pharmacologic (84 %, K = 0.685). The agreement between poor or fair image quality (27 of 36 cases, 75 %, K = 0.492) was not as good as for the good or excellent image quality cases (39 of 45 cases, 87 %, K = 0.755). Differences in concordance were noted for degree of ischemia with the majority of discordant interpretations (87 %) occurring in patients with no or mild LV myocardial ischemia. While site SE interpretations are largely concordant with core lab interpretations, this appears dependent on image quality and the extent of WMA. Thus core lab interpretations remain important in clinical trials where consistency of interpretation across a range of cases is critical. ClinicalTrials.gov NCT01471522. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Austria | 2 | 50% |
Japan | 1 | 25% |
Unknown | 1 | 25% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 75% |
Scientists | 1 | 25% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 42 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 6 | 14% |
Student > Ph. D. Student | 5 | 12% |
Student > Master | 5 | 12% |
Student > Doctoral Student | 3 | 7% |
Other | 3 | 7% |
Other | 7 | 17% |
Unknown | 13 | 31% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 10 | 24% |
Biochemistry, Genetics and Molecular Biology | 2 | 5% |
Computer Science | 2 | 5% |
Nursing and Health Professions | 2 | 5% |
Neuroscience | 2 | 5% |
Other | 5 | 12% |
Unknown | 19 | 45% |